The Eli Lilly Lawsuit: What Nobody’s Saying About Compound GLP-1 Safety
The Eli Lilly lawsuit highlights significant safety concerns regarding compounded GLP-1 medications. Eli Lilly is targeting compound pharmacies for using untested additives in mixing tirzepatide. The publication discusses the substantial marketing of these compounds, often aimed at new patients, without adequate guidance on transitions from bulk purchases or management of side effects. Compounding, originally designed for specific patient needs, has morphed into a business model lacking proper oversight. As compounded medications become scarce, patients face difficult choices about their treatment. The importance of a supportive infrastructure and clear patient guidance is emphasized throughout this ongoing legal situation.